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Abstract: Herbal medicines are widely used for treating liver diseases and generally regarded as safe
due to their extensive use in Traditional Chinese Medicine practice for thousands of years. However,
in recent years, there have been increased concerns regarding the long-term risk of Herb-Induced
Liver Injury (HILI) in patients with liver dysfunction. Herein, two representative Chinese herbal
medicines: one—Xiao-Chai-Hu-Tang (XCHT)—a composite formula, and the other—Radix Polygoni
Multiflori (Heshouwu)—a single herb, were analyzed by network pharmacology study. Based on the
network pharmacology framework, we exploited the potential HILI effects of XCHT and Heshouwu
by predicting the molecular mechanisms of HILI and identified the potential hepatotoxic ingredients
in XCHT and Heshouwu. According to our network results, kaempferol and thymol in XCHT and
rhein in Heshouwu exhibit the largest number of liver injury target connections, whereby CASP3,
PPARG and MCL1 may be potential liver injury targets for these herbal medicines. This network
pharmacology assay might serve as a useful tool to explore the underlying molecular mechanism of
HILI. Based on the theoretical predictions, further experimental verification should be performed to
validate the accuracy of the predicted interactions between herbal ingredients and protein targets in
the future.
Keywords: hepatoprotective Chinese herbal medicines; Xiao-Chai-Hu-Tang; Radix Polygoni Multiflori;
Herb-Induced Liver Injury; network pharmacology
1. Introduction
Herb-Induced Liver injury (HILI) refers to herbal drug-driven liver injuries which are a cause
of acute and chronic liver disease. Thousands of kinds of medicines have been implicated in causing
various liver injuries and this is the most common reason for a drug to be withdrawn from the
market [1].
Xiao-chai-hu-tang (XCHT), a Chinese herbal formula, is commonly used for treatment of chronic
hepatitis and liver fibrosis in East Asian countries such as China, Japan and Korea. According to
previous studies, XCHT exhibits various pharmacological properties including anti-inflammation,
antioxidant and anti-hepatic fibrosis [2,3]. In addition, XCHT has shown strong hepatoprotective effects
in both basic and clinical studies by regulating the immune response in the context of hepatitis C viral
infection [4,5]. There are currently ongoing clinical trials of XCHT for hepatitis C and liver cirrhosis
at the University of California, at San Diego and the Memorial Sloan-Kettering Cancer Center in the
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USA [5]. In spite of its multiple pharmacological effects, several systematic studies have examined and
challenged its clinical safety. In 1995, four patients in Japan treated with XCHT by oral administration
exhibited acute drug-induced liver injury [6]. In 2006, a case report in Taiwan also reminded us
of the probable HILI potential of XCHT [7]. In 2000, the Japanese Ministry of Health Department
completely forbade patients with hepatitis, liver cirrhosis and liver carcinoma to take XCHT [8].
The HILI of Radix Polygoni Multiflori (Heshouwu in Chinese) has also aroused widespread concern
in recent years. Heshouwu has been used as a hepatoprotective and anti-aging tonic in Traditional
Chinese Medicine (TCM) for thousands of years. In previous pharmacological studies, Heshouwu
showed hepatoprotective effects against liver inflammation, oxidation stress, nonalcoholic fatty liver
disease (NAFLD), liver fibrosis and cirrhosis as well as hepatic cancer [9,10]. However, increasing
evidence also showed that Heshouwu might lead to significant adverse drug reactions in liver. Many
case reports have revealed that long-term use of Heshouwu may induce toxic hepatitis or other severe
liver injury, and even death [11–13]. Recent study has evaluated the “dose-time-toxicity” relationship
of the HILI caused by Heshouwu in mice. The water-extracted components (from 5.5 to 30.75 g/kg)
and the ethanol-extracted components (from 8.5 to 24.5 g/kg) caused obvious damage to the liver
organization in a dose-dependent manner, resulting in increased serum alanine transaminase (ALT)
and aspartate transaminase (AST) levels [14,15]. A compilation of liver injury cases have established
causality for 28/57 different TCM herbal medicines, including Heshouwu and XCHT [14]. Although
these studies have indicated that Heshouwu and XCHT may cause side effects on the liver, there has
been insufficient scientific evidence to determine the HILI mechanisms of Heshouwu and XCHT.
In recent years, network pharmacology has made a significant contribution to investigating the
molecular mechanisms of action of Chinese herbal medicines through chemical pharmacokinetic
absorption, distribution, metabolism, excretion (ADME) property evaluation, target prediction and
network/pathway analysis. Network pharmacology analysis plays an important role in the effective
use of Chinese herbal medicines by predicating the potential toxic ingredients of candidate herbal
drugs. Herein, based on the network pharmacology framework, we analyzed the potential HILI
mechanisms of XCHT and Heshouwu. This network pharmacology technique could be of great help
in predicting the safety of traditional herbal medicines and promoting the herbal medicine-based
drug discovery.
2. Results and Discussion
2.1. Potential HILI Mechanisms of XCHT Predicted by Network Pharmacological Analysis
We have identified a total of 761 chemicals in XCHT. In multi-compound medicinal herbal mixtures
like XCHT, many compounds in that lack appropriate pharmaceutical properties are believed to fail
to reach the cellular targets, and thus exhibit little efficacy and should be neglected. The 438 XCHT
ingredients with satisfactory pharmacokinetic properties were predicted through an in silico-based
pharmacological method (Supplemental Table S1). The compounds and protein interaction analysis
results showed that a total of 676 intracellular targets were predicted to interact with the 438 ingredients
of XCHT. Among them, 51 are regarded as potential HILI targets. To further predict and illuminate the
relationships between these potential active compounds and hepatotoxic target genes, a drug-target
network were constructed (Figure 1). This network represents a global view of the potential compounds
(red triangles) and targets (blue rectangles) in XCHT, and it comprised 74 nodes (23 potential
compounds and 51 potential targets) and 131 edges (compound-target interactions). The degree
of nodes is a key topological parameter that characterizes the most influential nodes in a network,
and we used it to further determine the importance of active components and HILI targets [16].
Those high-degree nodes in the network, which had more compound-target interactions, are likely
to play a more important role in HILI [17,18]. Our network analysis results showed that various
candidate compounds in XCHT were linked to multiple targets, which may exhibit potential liver
injury effects. Among the 23 candidate compounds, kaempferol and thymol exhibit the largest number
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of liver injury targets connections (degree = 6), followed by saikosaponin D (degree = 5), coumestrol
(degree = 5), vanillin (degree = 5) and baicalein (degree = 5). For the 51 potential liver injury targets,
the network showed CASP3 had the largest number of compound-target interactions (saikosaponin
D, baicalin, nonenoic acid and mairin), followed by UGT1A10, UGT1A7, UGT1A8 (vanillin, thymol
and coumestrol), and MMP9 (vanillin, wogolin and baicalein). The remaining 46 targets showed
interactions with only two or one compounds. The information of 51 potential liver injury targets in
XCHT can be found in Table 1, where all the data were manually collected and integrated from the
STITCH, TTD, PharmGKB and CTD databases.
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Figure 1. Compound-target hepatotoxicity network of Xiao chai hu tang. This network represents
a global view of the potential compounds (red triangles) and targets (blue rectangles) in XCHT,
and it comprised 74 nodes (23 potential compounds and 51 potential targets) and 131 edges
(compound-target interactions).
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Table 1. The information of 51 potential HILI targets in Xiao chai hu tang.
Target Gene Target Protein Biolocigcal Activity of the Targeted Proteins
DECR1 2,4-dienoyl CoA reductase 1 fatty acid-oxidation
UGT1A8 UDP glucuronosyltransferase 1 family, polypeptide A8 liver enzyme essential to the disposal of bilirubin
UGT1A7 UDP glucuronosyltransferase 1 family, polypeptide A7 liver enzyme essential to the disposal of bilirubin
CASP8 caspase 8 hepatocyte apoptosis
UGT1A9 UDP glucuronosyltransferase 1 family, polypeptide A9 liver enzyme essential to the disposal of bilirubin
UGT1A10 UDP glucuronosyltransferase 1 family, polypeptide A10 liver enzyme essential to the disposal of bilirubin
CASP9 caspase 9 hepatocyte apoptosis
LTB4R2 leukotriene B4 receptor 2 inflammation
NCF1 neutrophil cytosolic factor 1 oxidation stress
PTGS2 prostaglandin-endoperoxide synthase 2 inflammation
CAT catalase oxidation stress
CES5A carboxylesterase 5A metabolism of xenobiotics in liver
CES2 carboxylesterase 2 metabolism of xenobiotics in liver
CASP3 caspase 3 hepatocyte apoptosis
PPARG peroxisome proliferator-activated receptorγ oxidation stress
PPARA peroxisome proliferator-activated receptorα oxidation stress
IL10 interleukin 10 inflammation
TNF tumor necrosis factor hepatocyte apoptosis
IL8 interleukin 8 viral infection
HADH hydroxyacyl-CoA dehydrogenase; fatty acid-oxidation
CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2 oxidation stress
PEX3 peroxisomal biogenesis factor 3 fatty acid-oxidation
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 oxidation stress
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 oxidation stress
MAPK8 mitogen-activated protein kinase 8 hepatocyte apoptosis
MAPK9 mitogen-activated protein kinase 9 hepatocyte apoptosis
UGT3A1 UDP glycosyltransferase 3 family, polypeptide A1 liver enzyme essential to the disposal of bilirubin
UGT3A3 UDP glycosyltransferase 3 family, polypeptide A3 liver enzyme essential to the disposal of bilirubin
UGT3A8 UDP glycosyltransferase 3 family, polypeptide A8 liver enzyme essential to the disposal of bilirubin
UGT3A7 UDP glycosyltransferase 3 family, polypeptide A7 liver enzyme essential to the disposal of bilirubin
UGT3A9 UDP glycosyltransferase 3 family, polypeptide A9 liver enzyme essential to the disposal of bilirubin
CASP3 caspase 3 hepatocyte apoptosis
NFE2L2 nuclear factor erythroid 2-related factor 2 oxidation stress
SELE E-selectin precursor hepatocyte apoptosis
APAF1 Apoptotic peptidase activating factor 1 hepatocyte apoptosis
TNFRSF10B tumor necrosis factor receptor superfamily member 10B hepatocyte apoptosis
ALDH3A1 aldehyde dehydrogenase 3 family, member A1; detoxification of alcohol-derived acetaldehyde in liver
ALOX12 arachidonate 12-lipoxygenase inflammation
MMP2 matrix metallopeptidase 2 liver fibrosis
MMP9 matrix metallopeptidase 9 liver fibrosis
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 oxidation stress
BECN1 beclin 1 viral infection
IL17A interleukin 17A inflammation
CCL2 chemokine (C-C motif) ligand 2 inflammation
TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 hepatocyte apoptosis
PAWR PRKC, apoptosis, WT1, regulator hepatocyte apoptosis
MMP9 matrix metallopeptidase 9 liver fibrosis
UGT1A3 UDP glucuronosyltransferase 1 family, polypeptide A3 liver enzyme essential to the disposal of bilirubin
UGT1A8 UDP glucuronosyltransferase 1 family, polypeptide A8 liver enzyme essential to the disposal of bilirubin
UGT1A9 UDP glucuronosyltransferase 1 family, polypeptide A9 liver enzyme essential to the disposal of bilirubin
UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1 liver enzyme essential to the disposal of bilirubin
Caspase 3 (CASP3), which had the largest number of compound interactions in our network
pharmacology study, was indicated as the potential key target of XCHT-induced liver injury. Previous
studies have indicated that CASP3 played an important role in liver diseases [19,20]. The hepatocyte
apoptosis induced by TNF-α is correlated with the activation of CASP3 [21,22]. Both in vitro and
in vivo studies confirmed that pancreatitis-associated ascitic fluid can induce hepatocyte apoptosis
and liver injury by activating CASP3 dependent pro-apoptotic pathways [23]. In addition, lower
expression of CASP3 can aggravate hepatic steatosis in NAFLD rat model by inducing hepatocyte
apoptosis [24]. Thus, we predicted that CASP3 might be a potential target for inducing liver injury by
XCHT. Saikosaponin D, baicalin, nonenoic acid and mairin from Radix bupleuri and Radix scutellariae
were expected as the possible liver injury ingredients in XCHT by targeting CASP3.
Uridine 5′-diphospho-glucuronosyltransferase (UGT) is a crucial enzyme family in liver for
detoxification and removal of exogenous compounds (e.g., dietary substances, drugs, toxins) and
endogenous substances (e.g., bilirubin, steroid hormones, and bile acids) [25–27]. In our compound-target
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network, UGT also plays a pivotal role in XCHT-induced liver injury. Literature review showed that
suppression of UGTs such as UGT1A10, UGT1A7, UGT1A8 by various endogenous or exogenous
factors not only reduced the ability of certain drugs’ glucuronidation and thus triggered clinical
adverse drug-drug interaction (clinical HILI), but also resulted in acute liver injury by metabolism
dysfunction of endogenous substances [28–30].
Matrix metalloproteinase 9 (MMP9) also showed multiple target-compound interactions in our
network study. Our in silico study showed MMP9 might play an important role in XCHT-induced liver
injury by inducing interstitial fibrosis in liver. Previous studies showed that MMP9 could be prognostic
markers for liver fibrosis [31]. MMP9 could modulate inflammation and extracellular matrix (ECM)
remodeling in liver. In vitro studies showed that MMP9 activity was critical for TGFβ2-induced matrix
contraction, and could promote hepatic fibrosis [32]. Down-regulation of MMP9 expression and the
TGF-β1/Smad signaling pathways could relieve liver fibrosis in vivo [33]. Further mechanism studies
demonstrated that during HILI process, Interleukin-1 produced by Kupffer cells or liver myofibroblast
cells might play a pivotal role in remodeling of hepatic fibrosis through an either p38-dependent or
p38-independent pathway to modulate the expression of MMP9 [34]. The above literature review
studies can partly support our network pharmacology analysis results of XCHT.
2.2. Potential HILI Mechanisms of Heshouwu Predicted by Network Pharmacological Analysis
We totally identified 73 major chemicals in Heshouwu. The sixteen ingredients with satisfactory
pharmacokinetic properties of Heshouwu were predicted through an in silico-based pharmacologic
method (Table 2). The compounds and proteins interaction analysis results showed that a total of
114 intracellular targets had potential interactions with the 16 ingredients of Heshouwu. Among them,
39 are regarded as potential HILI targets. To further predict and illuminate the relationship between
these potential liver injury compounds and HILI target genes, a drug-target network was constructed
(Figure 2). This network represents the interactions of the potential compounds (red triangles) and
targets (blue rectangles) in Heshouwu, which comprised 43 nodes (13 candidate compounds and
30 potential targets) and 62 edges (compound-target interactions). Our network analysis results
showed that various candidate compounds in Heshouwu were linked to multiple targets, which
may exhibit multiple liver injury effects. Among the 13 candidate compounds, rhein exhibits the
largest number of liver injury targets connections (degree = 7), followed by emodin (degree = 6) and
aloe-emodin (degree = 5). For the 30 potential liver injury targets, the network showed that PPARG
had the largest number of compound-target interactions (chrysazin, emodin anthrone, rhein and
butanedioic acid), followed by CASP3 (aloe-emodin, β-sitosterol and luteolin), and MCL1 (emodin,
rhein and quercetin). The remaining 27 targets showed interactions with only one or two compounds.
The information of the 30 potential liver injury targets in Heshouwu is shown in Table 3, where all the
data were manually collected and integrated from the STITCH, TTD, PharmGKB and CTD databases.
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Table 2. Compounds with satisfactory pharmacokinetic properties of Heshouwu.
Molecule Name Molecular Weight Oral Bioavailability (%) Predict Caco-2 Permeability
Physcion 284.28 32.29 0.52
Copaene 204.39 39.47 1.81
Luteolin 286.25 36.16 0.59
Quercetin 302.25 46.43 0.5
hexanoic acid 116.18 73.08 0.8
Kaempferol 286.25 41.88 0.64
Ethyl oleate 310.58 32.4 1.43
Squalene 410.8 33.55 2.08
Catechin 290.29 54.83 0.43
β-sitosterol 546.57 33.94 0.44
Butanedioic acid 118.1 39.62 0.44
Epicatechin 290.29 48.96 0.42
Gallic acid 170.13 31.69 0.69
Methyl gallate 184.16 30.91 0.66
4-hydroxybenzaldehyde 122.13 39.98 0.82
5-Dihydroxy-6-methyl-4(H)-pyran-4-one 144.14 37.8 0.48
Table 3. The information of 39 potential HILI targets in Heshouwu.
Target Gene Target Protein Biolocigcal Activity of the Targeted Proteins
RARA retinoic acid receptor alpha Adipogenesis
BCL2L1 bcl-2-like protein 1 isoform Bcl-X(L) hepatic apoptosis
PPARG peroxisome proliferator-activated receptor gamma AMPK pathways related fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways,such as fatty acid oxidation and glycolysis.
NFE2L2 nuclear factor erythroid 2-related factor 2 isoform 1 Oxidative Stress
RARA retinoic acid receptor alpha Adipogenesis
CYP19A1 cytochrome P450,family 19, subfamily A, polypeptide 1 Oxidation stress
MAPT Microtubule-associated protein tau AMPK pathways related fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways,such as fatty acid oxidation and glycolysis.
MCL1 Myeloid cell leukemia sequence 1 hepatic apoptosis
CYP1A2 cytochrome P450,family 1, subfamily A, polypeptide 2 Oxidation stress
NR1I3 nuclear receptor subfamily 1 group I member 3 lipid metabolism
PPARG peroxisome proliferator-activated receptor gamma AMPK pathways related fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways,such as fatty acid oxidation and glycolysis.
AHR aryl hydrocarbon receptor Adipogenesis
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Table 3. Cont.
Target Gene Target Protein Biolocigcal Activity of the Targeted Proteins
TP53 tumor protein p53 hepatic apoptosis
CASP9 caspase 9 hepatic apoptosis
CASP3 caspase 3 hepatic apoptosis
CASP8 caspase 8 hepatic apoptosis
XBP1 X-box binding protein 1 Transcription factor essential for hepatocyte growth
PPARG peroxisome proliferator-activated receptor gamma AMPK pathways related fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways,such as fatty acid oxidation and glycolysis.
PPARA peroxisome proliferator-activated receptor alpha lipid metabolism
NFE2L2 nuclear factor erythroid 2-related factor 2 isoform 1 Oxidative Stress
MAPT Microtubule-associated protein tau AMPK pathways related fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways,such as fatty acid oxidation and glycolysis.
PTPN7 tyrosine-protein phosphatase non-receptor type 7 isoform 2 AMPK pathways related fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways,such as fatty acid oxidation and glycolysis.
BCL2L1 bcl-2-like protein 1 isoform Bcl-X(L) hepatic apoptosis
MAPT Microtubule-associated protein tau AMPK pathways related fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways,such as fatty acid oxidation and glycolysis.
ALOX12 arachidonate 12-lipoxygenase, 12S-type hepatic inflammation
MMP9 matrix metallopeptidase 9 hepatic fibrosis
CASP3 caspase 3 hepatic apoptosis
MCL1 myeloid cell leukemia sequence 1 hepatic apoptosis
CYP2C8 cytochrome P450,family 2, subfamily C, polypeptide 8 oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics
DHCR24 24-dehydrocholesterol reductase oxidative stress
CCL3 chemokine (C-C motif) ligand 3 hepatic inflammation
SREBF2 sterol regulatory element binding transcription factor 2 lipid metabolism
CASP3 caspase 3 hepatic apoptosis
RXRA retinoid X nuclear receptor alpha fatty acid oxidation
PPARG peroxisome proliferator-activated receptor gamma AMPK pathways related fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways,such as fatty acid oxidation and glycolysis.
PPARD peroxisome proliferator-activated receptor delta Adipogenesis
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Interestingly, like XCHT, Heshouwu might also induce liver injury by targeting CASP3 according
to our network analysis. In addition, peroxisome proliferator-activated receptor gamma (PPARG)
and myeloid cell leukemia-1 (MCL1) are other two potential targets for Heshouwu-induced liver
injury. PPARG, also known as the glitazone receptor, could regulate fatty acid storage and glucose
metabolism. Inefficient fatty acid oxidation in mitochondria and increased oxidative damage are
features of NAFLD. In rodent models and patients with NAFLD, hepatic expression of PPARG
coactivator 1α (PPARGC1A) is inversely correlated with liver fat and disease severity. In mice,
loss of estrogen signaling contributes to oxidative damage caused by low levels of PPARGC1A in
liver, exacerbating steatohepatitis associated with high fructose and fat diets [35]. Furthermore,
a clinical study also found that genetic variation in PPARG was associated with NAFLD, and the minor
alleles haplotype was associated with inflammatory and fibrotic changes that denoted histologically
advanced NAFLD [36]. MCL1, belonging to the Bcl-2 family, can enhance cell survival via inhibiting
apoptosis [37]. Previous studies found that suppressing MCL1 could activate the mitochondrial
apoptotic pathway in hepatocytes and induce tumorigenesis [38]. In addition, knockout of MCL1 can
increase hepatic apoptosis in mice deregulating the expression of MCL1 may contribute to HILI [39].
The above statements partly support our network pharmacology analysis results of Heshouwu.
3. Materials and Methods
The protocol of the integrated network pharmacology approach includes four main steps as
follows (Figure 3).
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3.1. Molecular Database Construction
All of the known ingredients of XCHT or Heshouwu were manually collected from related literature
and two phytochemical databases: Traditional Chinese Medicine Systems Pharmacology Database
(TCMSP, http://ibts.hkbu.edu.hk/LSP/tcmsp.php) and TCM Database@Taiwan (http://tcm.cmu.edu.
tw/). The ingredients for these herbal medicines were retrieved from the above databases by using the
following search terms: Heshouwu, Radix Polygoni Multiflori, xiao chai hu tang, Sho-saiko-to.
3.2. Pharmacokinetic ADME Evaluation
In this step, an in silico integrative model~ADME was used to select the ingredients with
favorable pharmacokinetics properties. The ADME system used in this study including predict
oral bioavailability (PreOB) and predict Caco-2 permeability (PreCaco-2). Oral bioavailability (OB) is
one of the most vital pharmacokinetic properties of orally administered drugs as it plays an important
role for the efficiency of the drug delivery to the systemic circulation [40,41] Here, a reliable in silico
screening model (OBioavail 1.1) was employed in OB value calculation of the constituents in XCHT
and Heshouwu. This model was constructed based on 805 structurally diverse drugs and drug-like
molecules. Multiple linear regression, partial least square and support vector machine methods were
applied during this model building, ending up with determination coefficient (R2) = 0.80 and standard
error of estimate (SEE) = 0.31 for test sets [42,43]. In addition, for orally administered drugs, another
pivotal problem is their movement across the intestinal epithelial barrier, which determines the rate
and extent of human absorption and ultimately affects its bioavailability [44]. Thus, a preCaco-2
model was used to predict the drug absorption. The phytochemical information of the compounds
with their Caco-2 permeability properties were explored using the TCMSP database, the detailed
parameters’ information, screening criteria and calculation can be obtained from TCMSP website
(http://ibts.hkbu.edu.hk/LSP/tcmsp.php). Finally, compounds with OB ≥ 33% and Caco2 ≥ 0.4
cm/s were regarded as active ingredients for further study. It is worth noting that the OB values of
saikosaponin d and saikosaponin A are lower than 33%, but both of them are widely expected to
induce liver injury in vitro and in vivo, thus, these two additional compounds were also regarded as
candidate compounds [45].
3.3. Identification Targets for Potential HILI
In order to build the compound-target interaction profiles in XCHT and Heshouwu, we analyzed
the chemical compounds and protein interactions integrated from the Search Tool for Interactions
of Chemicals and Proteins (STITCH) 5.0 database (http://stitch.embl.de/) and Herbal Ingredients’
Targets (HIT) Database (http://lifecenter.sgst.cn/hit/), which are both databases of known and
predicted interactions between chemicals and proteins. These databases were based on text mining and
molecular docking technology to predict compound-protein interaction, which has been applied in the
research of TCM for discovering potential active ingredients and interpreting molecular mechanisms of
herbal medicines [46,47]. The STITCH 5.0 database can be used to study potential interactions between
300,000 phytochemicals and 2.6 million proteins curated from 1133 organisms. In this database,
the approximate probability of a predicted association for a chemical–protein interaction is determined
by the confidence score, with a higher score indicating a stronger interaction (low confidence score
~0.2; medium confidence score ~0.5; high confidence score ~0.75; highest confidence score ~0.95,
provided by STITCH 5.0 database). The HIT database is a publicly available research resource that
includes more than 116,000 interactions between 9300 chemicals and 13,300 genes. Both databases
were searched independently by two researchers to minimize any bias. Then, to better define the
HILI of XCHT or Heshouwu, Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/ttd/),
PharmGKB (http://www.pharmgkb.org) and Comparative Toxicogenomics Database (CTD, http:
//ctdbase.org/) [48–50] were employed to eliminate the noise and exclude irrelevant targets obtained
from above steps. The targets for HILI were retrieved from above database by using the following
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search terms: Liver injury, hepatic damage, hepatic toxicity, hepatic drug metabolism, fatty liver,
steatosis, lipid metabolism, liver fibrosis, oxidative damage, oxidative stress, liver inflammation,
hepatocyte apoptosis, hepatocellular necrosis and hepatogenic jaundice. Only the targets of Homo
sapiens were kept for further analysis.
3.4. Network Construction and Analzysis
To further explore the relationships between the compounds and targets associated with
hepatotoxic effects, the Compound–Target network plotting was generated by Cytoscape 3.4.0
(http://www.cytoscape.org/) [51]. In the graphical network plot, nodes represent the compounds or
proteins, and edges encode the compound–target interactions. In order to specify the importance of a
node and how this node influences the communication between two nodes, all the properties of the
network were analyzed by Network Analysis plugin.
4. Conclusions
Chinese herbal medicines are multi-component synergistic systems, which might play both
therapeutic and toxic roles in humans. The HILI and quality control of herbal formulas or single
herbs for public consumption are one of increasing concerns these days due to the lack of scientific
evidence on their safety. In this paper, two drug-target networks of HILI of XCHT and Heshouwu were
constructed through network pharmacology assays. The network predicted the potential underlying
HILI mechanism of XCHT and Heshouwu and elucidated the interrelationship between hepatic toxicity
and Chinese herbal medicine interventions. Therefore, network pharmacology is a useful tool to reveal
the potential mechanism of HILI of Chinese herbal medicines and potential toxic ingredients. These
data in our study, if combined with further in vitro and in vivo studies, should facilitate construction
of a potential herb-induced liver injury network and improve the specificity of toxicity prediction for
future drug candidates. Notwithstanding the advances in recent network pharmacology research, there
are some crucial technical issues to be addressed and improved for data collection of herb-induced
liver injury. First of all, the inventory of herbal products remains incomplete and new chemical
structures are continuously being discovered. Secondly, previous researchers have explored and
identified only a small part of the hepatotoxic target genes. Last but not least, stringently assessing the
relationships between compounds and corresponding targets and obtaining accurate action modes such
as activated drug-target interactions or inhibited drug-target interactions are still a challenge for present
network pharmacology study. Despite these technical issues, for the multiple components-multiple
targets interaction model of herbal medicines, conventional experimental research faces a situation
of long-term investment to investigate the complex interaction mechanisms. Thus, our network
pharmacology study which integrates the systems biology and in-silico technologies may offer a
direction for the mechanism study of HILI. The high degree nodes, which may play hub roles in the
compound-target network, will provide potential key object for next experimental study. Our results
not only provide new insights for a deeper understanding of the molecular basis of potential HILI
but also demonstrate a promising method for assessing the drug’s safety from herbal medicine.
As further steps, herbal compound libraries should be established and further enriched to better
correlate compound functions with structures. Experimental verification is also urgently needed to
validate the accurate interactions between the predicted active ingredients and target proteins.
Supplementary Materials: Supplementary materials are available online. Table S1: Compounds with satisfactory
pharmacokinetic properties of XCHT.
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